Atrial septal defect percutaneous closure: Difference between revisions
No edit summary |
|||
| Line 7: | Line 7: | ||
==Percutaneous closure== | ==Percutaneous closure== | ||
Percutaneous transcatheter closure is current only indicated for the closure of [[Atrial septal defect ostium secundum|ostium secundum atrial septal defects]]. It should not be used in patients with [[Atrial septal defect sinus venosus|sinus venosus]], [[Atrial septal defect ostium primum|primum]] or [[Atrial septal defect patent foramen ovale|patent foramen ovale]] atrial septal defects. In patients with a secundum defect, there must be a sufficient rim of tissue around the septal defect. | Percutaneous transcatheter closure is current only indicated for the closure of [[Atrial septal defect ostium secundum|ostium secundum atrial septal defects]]. It should not be used in patients with [[Atrial septal defect sinus venosus|sinus venosus]], [[Atrial septal defect ostium primum|primum]] or [[Atrial septal defect patent foramen ovale|patent foramen ovale]] atrial septal defects. In patients with a secundum defect, there must be a sufficient rim of tissue around the septal defect. | ||
In a study done on 236 patients with secundum atrial septal defects (ASD), to evaluate the safety and efficacy of transcatheter closure with the amplatzer septal occlude, the device was found to be very efficient. It causes atrial septal defect closure in 84.7% of the treated patient population. During a median follow up of 2.3 years complete closure was documented in 94%, with a residual shunt only in 12 patients. Two of the treated patients were reported to have procedure related complications like retroperitoneal bleeding and air embolism. | |||
The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:<ref name="pmid11829678">{{cite journal| author=Schwetz BA| title=From the Food and Drug Administration. | journal=JAMA | year= 2002 | volume= 287 | issue= 5 | pages= 578 | pmid=11829678 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11829678 }} </ref> | The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:<ref name="pmid11829678">{{cite journal| author=Schwetz BA| title=From the Food and Drug Administration. | journal=JAMA | year= 2002 | volume= 287 | issue= 5 | pages= 578 | pmid=11829678 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11829678 }} </ref> | ||
Revision as of 16:35, 25 August 2011
|
Atrial Septal Defect Microchapters | |
|
Treatment | |
|---|---|
|
Surgery | |
|
| |
|
Special Scenarios | |
|
Case Studies | |
|
Atrial septal defect percutaneous closure On the Web | |
|
American Roentgen Ray Society Images of Atrial septal defect percutaneous closure | |
|
Risk calculators and risk factors for Atrial septal defect percutaneous closure | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [[2]]; Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [[4]]
Overview
Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in ostium secundum patients.
Percutaneous closure
Percutaneous transcatheter closure is current only indicated for the closure of ostium secundum atrial septal defects. It should not be used in patients with sinus venosus, primum or patent foramen ovale atrial septal defects. In patients with a secundum defect, there must be a sufficient rim of tissue around the septal defect.
In a study done on 236 patients with secundum atrial septal defects (ASD), to evaluate the safety and efficacy of transcatheter closure with the amplatzer septal occlude, the device was found to be very efficient. It causes atrial septal defect closure in 84.7% of the treated patient population. During a median follow up of 2.3 years complete closure was documented in 94%, with a residual shunt only in 12 patients. Two of the treated patients were reported to have procedure related complications like retroperitoneal bleeding and air embolism.
The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:[1]
- Amplatzer septal occluder
- CardioSEAL
- HELEX septal occluder
- Sideris patch
The Ampltazer septal occluder (ASO) is the most commonly used device as it allows closure of large cavities, is easy to implant, and boasts high success rates. As an instrument, the ASO consists of two self-expandable round discs connected to each other with a 4-mm waist, made up of 0.004–0.005´´ nitinol wire mesh filled with Dacron fabric. Implantation of the device is relatively easy. The prevalence of residual defect is low. The disadvantages are a thick profile of the device and concern related to a large amount of nitinol (a nickel-titanium compound) in the device and consequent potential for nickel toxicity.
<youtube v=Gros-u7YCTk/>
<youtube v=4c3CEgjj2PY/>
Evaluation
Benefits of percutaneous closure
Complications of percutaneous closure
References
- ↑ Schwetz BA (2002). "From the Food and Drug Administration". JAMA. 287 (5): 578. PMID 11829678.